KRIYA GENE THERAPY EUROPE LIMITED

Kriya Gene Therapy Europe Limited is a biopharmaceutical company dedicated to redefining gene therapy. By developing life‑changing treatments for diseases that affect millions worldwide, Kriya aims to make gene‑based medicines accessible not just to a few, but to the many who need them.

The company’s pipeline focuses on three high‑unmet‑need areas: ophthalmology (targeting thyroid‑eye disease), metabolic disorders (including MASH and other undisclosed conditions), and neurology. Leveraging validated biological pathways and innovative gene‑delivery platforms, Kriya seeks to deliver transformative benefits to patients across these therapeutic fields.

Since its founding in 2019, Kriya has attracted leading healthcare and technology investors, raising more than €900 million, including a recent €320 million Series D round to accelerate its chronic‑disease programmes. Recent appointments of Sachiyo Minegishi as Chief Financial Officer and Greg Di Russo, MD, as Chief Medical Officer underscore the company’s commitment to robust scientific and commercial leadership. Kriya’s mission is clear: to bring cutting‑edge gene therapies to the broadest possible patient population.